Elan Investors Approve Buyback in Setback to Royalty

Elan Investors Approve Buyback in Setback to Royalty

Barry Cronin/Bloomberg

Royalty Pharma had offered $13 in cash for each American depositary receipt, plus $2.50 if certain sales and development goals are met.